Short Interest in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Grows By 8.4%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 3,630,000 shares, a growth of 8.4% from the November 30th total of 3,350,000 shares. Approximately 4.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 539,100 shares, the short-interest ratio is presently 6.7 days.

Centessa Pharmaceuticals Trading Up 2.4 %

Shares of Centessa Pharmaceuticals stock opened at $16.75 on Thursday. Centessa Pharmaceuticals has a 52-week low of $6.65 and a 52-week high of $18.97. The firm has a market capitalization of $2.21 billion, a PE ratio of -10.95 and a beta of 1.52. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company’s fifty day moving average price is $16.80 and its two-hundred day moving average price is $14.03.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CNTA. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Jefferies Financial Group boosted their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target on the stock. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.83.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $17.66, for a total value of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at $3,236,477.56. This represents a 5.17 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Saurabh Saha sold 22,205 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $15.80, for a total value of $350,839.00. Following the completion of the transaction, the chief executive officer now directly owns 663,456 shares in the company, valued at $10,482,604.80. The trade was a 3.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 368,023 shares of company stock worth $6,335,574. Corporate insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP increased its holdings in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares in the last quarter. Sandia Investment Management LP acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter worth approximately $90,000. Finally, Fred Alger Management LLC bought a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.